Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
11 July 2024 - 9:03PM
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage
biotechnology company developing therapies for patients with kidney
disease (the “Company or “Unicycive”), today announced that Shalabh
Gupta, M.D., Chief Executive Officer will participate in a Fireside
Chat at the H.C. Wainwright 3rd Annual Kidney Virtual
Conference on Monday, July 15, 2024 at 2:00 p.m. ET.
A link to the live and archived webcast may be
accessed on the Unicycive website under the Investors section:
Events and Presentations. An archive of the webcast will be
available for three months.
About Unicycive
Therapeutics
Unicycive Therapeutics is a biotechnology
company developing novel treatments for kidney diseases.
Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a
novel investigational phosphate binding agent being developed for
the treatment of hyperphosphatemia in chronic kidney disease
patients on dialysis. UNI-494 is a patent-protected new chemical
entity in clinical development for the treatment of conditions
related to acute kidney injury. For more information, please
visit Unicycive.com and follow us on LinkedIn, X, and YouTube.
Investor Contact:
ir@unicycive.com(650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
Unicycive Therapeutics (NASDAQ:UNCY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Unicycive Therapeutics (NASDAQ:UNCY)
Historical Stock Chart
From Sep 2023 to Sep 2024